Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Genmab AS (GNMSF)
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Genmab AS retains a regular Real Value of $289.01 per share. The prevalent price of the firm is $290.38. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Current Valuation of 26.41 B, return on equity of 0.24, and Return On Asset of 0.1 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage locking in undervalued assets and disposing overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Incyte (INCY)
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. The entity currently falls under 'Large-Cap' category with a current market capitalization of 11.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte's market, we take the total number of its shares issued and multiply it by Incyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year. This firm currently falls under 'Mega-Cap' category with a current market capitalization of 101.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Vertex Pharmaceuticals has a current Real Value of $397.55 per share. The regular price of the company is $393.48. Our model measures the value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of 0.23, shares outstanding of 258.46 M, and Operating Margin of 0.38 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
CSL (CSLLY)
The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1338 %, meaning that it generated $0.1338 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mega-Cap' category with a current market capitalization of 103.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CSL's market, we take the total number of its shares issued and multiply it by CSL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
CSL Limited (CMXHF)
The company has return on total asset (ROA) of 0.0798 % which means that it generated a profit of $0.0798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1964 %, meaning that it generated $0.1964 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mega-Cap' category with a current market capitalization of 102.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CSL's market, we take the total number of its shares issued and multiply it by CSL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. CSL Limited shows a prevailing Real Value of $162.19 per share. The current price of the firm is $172.54. Our model approximates the value of CSL Limited from analyzing the firm fundamentals such as Operating Margin of 0.28 %, profit margin of 0.21 %, and Return On Equity of 0.2 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point future time, asset prices and their ongoing real values will blend.
Neurocrine Biosciences (NBIX)
The company has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year. The firm currently falls under 'Large-Cap' category with a current market capitalization of 13.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 43.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seagen's market, we take the total number of its shares issued and multiply it by Seagen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
United Therapeutics (UTHR)
The company has return on total asset (ROA) of 0.1122 % which means that it generated a profit of $0.1122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1827 %, meaning that it created $0.1827 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 04/19/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M. This firm currently falls under 'Large-Cap' category with a current market capitalization of 11.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate United Therapeutics's market, we take the total number of its shares issued and multiply it by United Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Genmab AS (GNMSF)
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Genmab AS retains a regular Real Value of $289.01 per share. The prevalent price of the firm is $290.38. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Current Valuation of 26.41 B, return on equity of 0.24, and Return On Asset of 0.1 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage locking in undervalued assets and disposing overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Incyte (INCY)
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. The entity currently falls under 'Large-Cap' category with a current market capitalization of 11.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte's market, we take the total number of its shares issued and multiply it by Incyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year. This firm currently falls under 'Mega-Cap' category with a current market capitalization of 101.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Vertex Pharmaceuticals has a current Real Value of $397.55 per share. The regular price of the company is $393.48. Our model measures the value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of 0.23, shares outstanding of 258.46 M, and Operating Margin of 0.38 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
CSL (CSLLY)
The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1338 %, meaning that it generated $0.1338 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mega-Cap' category with a current market capitalization of 103.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CSL's market, we take the total number of its shares issued and multiply it by CSL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
CSL Limited (CMXHF)
The company has return on total asset (ROA) of 0.0798 % which means that it generated a profit of $0.0798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1964 %, meaning that it generated $0.1964 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mega-Cap' category with a current market capitalization of 102.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CSL's market, we take the total number of its shares issued and multiply it by CSL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. CSL Limited shows a prevailing Real Value of $162.19 per share. The current price of the firm is $172.54. Our model approximates the value of CSL Limited from analyzing the firm fundamentals such as Operating Margin of 0.28 %, profit margin of 0.21 %, and Return On Equity of 0.2 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point future time, asset prices and their ongoing real values will blend.
Neurocrine Biosciences (NBIX)
The company has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year. The firm currently falls under 'Large-Cap' category with a current market capitalization of 13.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 43.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seagen's market, we take the total number of its shares issued and multiply it by Seagen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
United Therapeutics (UTHR)
The company has return on total asset (ROA) of 0.1122 % which means that it generated a profit of $0.1122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1827 %, meaning that it created $0.1827 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 04/19/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M. This firm currently falls under 'Large-Cap' category with a current market capitalization of 11.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate United Therapeutics's market, we take the total number of its shares issued and multiply it by United Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio Optimization Now
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
